Prairiewood Capital LLC Sells 4,631 Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)

Prairiewood Capital LLC reduced its stake in shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) by 11.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 34,675 shares of the biotechnology company’s stock after selling 4,631 shares during the period. Prairiewood Capital LLC’s holdings in Ironwood Pharmaceuticals were worth $154,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. State Street Corp raised its stake in shares of Ironwood Pharmaceuticals by 7.3% in the 3rd quarter. State Street Corp now owns 9,919,865 shares of the biotechnology company’s stock valued at $40,870,000 after acquiring an additional 677,024 shares in the last quarter. Charles Schwab Investment Management Inc. grew its holdings in Ironwood Pharmaceuticals by 23.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,904,271 shares of the biotechnology company’s stock valued at $7,846,000 after purchasing an additional 364,841 shares during the last quarter. FMR LLC raised its position in shares of Ironwood Pharmaceuticals by 25.1% in the third quarter. FMR LLC now owns 169,681 shares of the biotechnology company’s stock valued at $699,000 after purchasing an additional 34,089 shares during the period. Weiss Asset Management LP acquired a new stake in shares of Ironwood Pharmaceuticals in the third quarter worth $893,000. Finally, Pacer Advisors Inc. boosted its holdings in shares of Ironwood Pharmaceuticals by 26.6% during the 3rd quarter. Pacer Advisors Inc. now owns 11,279,822 shares of the biotechnology company’s stock worth $46,473,000 after buying an additional 2,372,183 shares during the period.

Ironwood Pharmaceuticals Trading Down 3.2 %

Shares of Ironwood Pharmaceuticals stock opened at $3.66 on Tuesday. The company has a market cap of $585.71 million, a price-to-earnings ratio of -122.00 and a beta of 0.34. Ironwood Pharmaceuticals, Inc. has a 1 year low of $3.06 and a 1 year high of $15.70. The company’s fifty day simple moving average is $3.94 and its 200-day simple moving average is $4.62.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last posted its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.09 by ($0.07). Ironwood Pharmaceuticals had a negative return on equity of 0.96% and a negative net margin of 0.65%. The company had revenue of $91.60 million for the quarter, compared to the consensus estimate of $91.22 million. During the same quarter in the previous year, the firm posted $0.12 EPS. The business’s revenue for the quarter was down 19.4% compared to the same quarter last year. As a group, research analysts forecast that Ironwood Pharmaceuticals, Inc. will post 0.08 earnings per share for the current fiscal year.

Insider Activity at Ironwood Pharmaceuticals

In other Ironwood Pharmaceuticals news, CFO Sravan Kumar Emany sold 11,001 shares of the business’s stock in a transaction on Monday, November 18th. The shares were sold at an average price of $4.08, for a total value of $44,884.08. Following the sale, the chief financial officer now owns 309,572 shares of the company’s stock, valued at $1,263,053.76. The trade was a 3.43 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 12.90% of the company’s stock.

Analyst Ratings Changes

Separately, StockNews.com lowered shares of Ironwood Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, November 12th. Three equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $10.40.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.